Monica E. Luchi
Incyte
10 Papers
156 Citations
Monica E. Luchi is an academic researcher from Incyte. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 7, co-authored 9 publications. Previous affiliations of Monica E. Luchi include Eli Lilly and Company.
Chat about Author
Papers
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Edward C. Keystone,Peter C. Taylor,E. Drescher,Douglas E Schlichting,Scott D. Beattie,Pierre-Yves Berclaz,Chin Lee,Rosanne Fidelus-Gort,Monica E. Luchi,Terence Rooney,William L. Macias,Mark C. Genovese +11 more
TL;DR: Baricitinib improved the signs and symptoms of RA in methotrexate inadequate responders with active disease and was well tolerated with no unexpected safety findings through week 24.
269
Patent
Janus kinase inhibitors for treatment of dry eye and other eye related diseases
Paul A. Friedman,Jordan S. Fridman,Monica E. Luchi,William V. Williams +3 more
- 01 Oct 2009
TL;DR: In this paper, methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, Kits, and Compositions utilize a JAK inhibitor.
85
JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy
Kris Vaddi,Monica E. Luchi +1 more
TL;DR: Emerging clinical results demonstrate that JAK inhibition is a validated new mechanism for the development of oral DMARD agents that is likely to join the armamentarium against RA in the near future.
29
LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis
Edward C. Keystone,Peter C. Taylor,Mark C. Genovese,Douglas E Schlichting,Scott D. Beattie,Carol L. Gaich,R. Fidelus Gort,Monica E. Luchi,William L. Macias +8 more
TL;DR: The primary endpoint to evaluate the efficacy of LY was assessed by the combined proportion of pts in the 4-mg and 8-mg dose groups who achieved an ACR20 response compared to PBO over 12 weeks, and onset of efficacy was rapid for ACR 20, ACR50,ACR70, and DAS28-CRP.
18
•Journal Article
24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
Mark C. Genovese,E.C. Keystone,Peter C. Taylor,E. Drescher,Berclaz P-Y.,Chin Lee,Douglas E Schlichting,Scott D. Beattie,Rosanne Fidelus-Gort,Monica E. Luchi,William L. Macias +10 more
16